Physician profile
Armen I Simonian
NPI 1972566263
$4,339.72
in general payments reported to CMS, 2019-2025
28 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $838 · 2021: $872 · 2022: $913 · 2023: $514 · 2024: $29.92 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,630.86 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $783.14 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $370.01 | 2019-2023 | Entyvio |
| Merck Sharp & Dohme LLC | $189.09 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $187.85 | 2020-2023 | Linzess |
| Pfizer INC. | $182.03 | 2019-2023 | |
| Daiichi Sankyo INC. | $129.21 | 2019-2023 | Injectafer |
| Janssen Biotech, INC. | $125.41 | 2019-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $115.88 | 2019-2021 | |
| Gilead Sciences, INC. | $82.02 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $74.01 | 2023 | Terlivaz |
| Redhill Biopharma INC. | $65.12 | 2020-2021 | |
| Allergan, INC. | $53.37 | 2019-2020 | |
| Qol Medical, LLC | $53.03 | 2021-2022 | |
| Vivus LLC | $44.88 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28.65 | 2023 | Gi Genius |
| Braintree Laboratories, INC. | $28.44 | 2021-2022 | |
| Alfasigma USA, INC. | $28.05 | 2020-2021 | |
| Celgene Corporation | $26.57 | 2022-2023 | Zeposia |
| Sanofi Pasteur INC. | $19.25 | 2023 | |
| Covidien LP | $17.60 | 2019 | |
| Ambu INC. | $17.13 | 2025 | |
| Dynavax Technologies Corporation | $16.81 | 2022 | |
| Ardelyx, INC. | $15.92 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.62 | 2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $14.46 | 2024 | Voquezna |
| W. L. Gore & Associates, INC. | $14.19 | 2023 | Gore Cardioform Septal Occluder |
| Pharmacosmos Therapeutics INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armen Simonian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.